Breast Cancer Risk Lower Among Regular Coffee Drinkers
May 15, 2011 by · Leave a Comment
Women who drink coffee regularly have a significantly lower risk of developing antiestrogen-resistant estrogen-receptor (ER)-negative breast cancer, researchers from the Karolinska Institute, Sweden, revealed in Breast Cancer Research. Breast cancer may be sub-divided into hormone-responsive (estrogen receptor (ER) positive) and non-hormone-responsive subtypes (ER-negative)…
Coffee Reduces Breast Cancer Risk
May 12, 2011 by · Leave a Comment
Recently published research shows that coffee drinkers enjoy not only the taste of their coffee but also a reduced risk of cancer with their cuppa. More detailed research published today in BioMed Central’s open access journal Breast Cancer Research shows that drinking coffee specifically reduces the risk of antiestrogen-resistant estrogen-receptor (ER)-negative breast cancer…
Ausio Pharmaceutical's ER(beta) Agonist AUS-131 Is Well Tolerated In First Human Clinical Trials
April 4, 2011 by · Leave a Comment
Results of two Phase 1 clinical trials of S-equol (AUS-131) were published in the February issue of Menopause: The Journal of the North American Menopause Society. This first-in-class, nonsteroidal, nonhormonal estrogen receptor beta (ERbeta) agonist offers a potentially safer alternative to estrogen for the treatment of menopausal symptoms…
Ausio Pharmaceutical's ER(beta) Agonist AUS-131 Is Well Tolerated In First Human Clinical Trials
March 31, 2011 by · Leave a Comment
Results of two Phase 1 clinical trials of S-equol (AUS-131) were published in the February issue of Menopause: The Journal of the North American Menopause Society. This first-in-class, nonsteroidal, nonhormonal estrogen receptor beta (ERbeta) agonist offers a potentially safer alternative to estrogen for the treatment of menopausal symptoms…
Ausio Pharmaceutical's ER(beta) Agonist AUS-131 Is Well Tolerated In First Human Clinical Trials
March 28, 2011 by · Leave a Comment
Results of two Phase 1 clinical trials of S-equol (AUS-131) were published in the February issue of Menopause: The Journal of the North American Menopause Society. This first-in-class, nonsteroidal, nonhormonal estrogen receptor beta (ERbeta) agonist offers a potentially safer alternative to estrogen for the treatment of menopausal symptoms…
